Economic Impact of a Genomic Companion Diagnostic Test for Breast Cancer Patients in French Private Hospitals

Economic Impact of a Genomic Companion Diagnostic Test for Breast Cancer Patients in French Private Hospitals

2014 Value in health

Vataire, A.L. | Aballea, S. | Katz, G. | Volume: 17, Issue: 7, Pages: A623, V,

Several multigene prognostic and predictive tests have recently been launched. The 21-gene assay (OncotypeDX®), a validated gene expression profiling test that predicts the likelihood of adjuvant chemotherapy benefit in patients with early stage breast cancer, was found to be cost-effective and recommended in several guidelines. Its use in clinical practice in France is limited because of the absence of reimbursement. This study aims to determine if the utilisation of the 21-gene assay in private hospitals would provide good value for money from a collective perspective in France and whether hospitals can afford using the test under the current payment system.

https://www.doi.org/10.1016/j.jval.2014.08.2214; 10.1016/j.jval.2014.08.2214